Cargando…
Dapagliflozin: A Review in Type 2 Diabetes
Dapagliflozin (Forxiga(®)) is a highly potent, reversible and selective sodium-glucose cotransporter-2 inhibitor indicated worldwide for the treatment of type 2 diabetes (T2D). In the EU, oral dapagliflozin once daily is approved for use as monotherapy (in patients who are intolerant of metformin) a...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879440/ https://www.ncbi.nlm.nih.gov/pubmed/31236801 http://dx.doi.org/10.1007/s40265-019-01148-3 |